Prosecution Insights
Last updated: May 29, 2026
Application No. 17/637,565

COMPOSITION FOR PREVENTING OR TREATING BACTERIAL INFECTIOUS DISEASE COMPRISING 4-GINGEROL DERIVATIVE COMPOUND AS ACTIVE INGREDIENT

Non-Final OA §102§112
Filed
Apr 27, 2022
Priority
Aug 23, 2019 — RE 10-2019-0103522 +2 more
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Korea University Research And Business Foundation
OA Round
3 (Non-Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
71%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
871 granted / 1227 resolved
+11.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
97 currently pending
Career history
1279
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
20.1%
-19.9% vs TC avg
§102
27.4%
-12.6% vs TC avg
§112
24.1%
-15.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1227 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 2. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on March 16, 2026 has been entered. Response to Amendment 3. The amendments to the claims filed on March 16, 2026 have been fully considered. The amendments are sufficient to overcome the 35 USC 102 rejection over RN 1817-51-2. 4. The amendments are not sufficient to overcome the 35 USC 102 rejection over RN 53247-50-0. Below are responses to Applicant’s remarks. The claims were previously rejected as being anticipated by RN 53247-50-0. Applicants have amended the claims, however, claim 5 still contains the prior art compound. The heading of [Formula 13b] has been deleted, however, the compound is still claimed. This ground of rejection is withdrawn for claims 1, 5 and 6. The rejection is maintained for claim 5. 5. Notwithstanding non-allowability of the claims, the search and examination was extended. Prior art was found that anticipates the amended Markush claims. Therefore, the claims were rejected and claims to nonelected species were held withdrawn from consideration. The claims were further searched to the nonelected species shown in this office action. 6. A new ground of rejection is necessitated by the claim amendments. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 7. Claim 5 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claim refers to compound of Formula 21, and Formula 30 to Formula 32. However, the claims are directed to far more compounds than Formula 21, and Formula 30 to Formula 32. For this reason, the scope of the claims cannot be ascertained. If Applicant’s intention is to have this claim directed only to Formula 21, and Formula 30 to Formula 32, it is suggested for Applicants to strike through the remaining structures which are not Formula 21, and Formula 30 to Formula 32. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. 8. Claim(s) 1, 5 and 6 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 1892528-68-5 ( PNG media_image1.png 230 452 media_image1.png Greyscale ). The reference has a publication date of April 18, 2016 which antedates the present claims having an effective filing date of August 21, 2020. The compound corresponds to the present claims in the following manner: X/Y=H/hal; L=triple bond; OR2=O; R1=C3 alkyl. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUN JAE YOO/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Apr 27, 2022
Application Filed
May 15, 2025
Non-Final Rejection mailed — §102, §112
Sep 15, 2025
Response Filed
Dec 16, 2025
Final Rejection mailed — §102, §112
Mar 16, 2026
Request for Continued Examination
Mar 18, 2026
Response after Non-Final Action
Mar 24, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12637455
NAPHTHYRIDINE AND PYRIDO[3,4-c]PYRIDAZINE DERIVATIVES AS GABAA ALPHA 5 RECEPTOR MODULATORS
3y 8m to grant Granted May 26, 2026
Patent 12636280
Therapeutic Tyrosine Kinase Inhibitors for Relapsing Multiple Sclerosis (RMS)
2y 2m to grant Granted May 26, 2026
Patent 12635400
ORGANOMETALLIC COMPOUND AND APPLICATION THEREOF
2y 6m to grant Granted May 19, 2026
Patent 12623997
Non-Coordinating Anion Activators Containing a Cation with Long Chain Alkoxy Functionalization
4y 0m to grant Granted May 12, 2026
Patent 12612377
PROCESS FOR PREPARING AMINOFURANES
3y 3m to grant Granted Apr 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
71%
With Interview (+0.0%)
2y 8m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1227 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month